(2R,3S,4R,5R)-5-[6-((1S,2S)-2-butyryloxycyclopentylamino)purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-ylmethyl butyrate | 1337911-73-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3S,4R,5R)-5-[6-((1S,2S)-2-butyryloxycyclopentylamino)purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-ylmethyl butyrate
• 英文别名: [(2R,3S,4R,5R)-5-[6-[[(1S,2S)-2-butanoyloxycyclopentyl]amino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl butanoate
• CAS: 1337911-73-5
• 化学式: C₂₃H₃₃N₅O₇
• 分子量: 491.544
• InChiKey: COTABKIEHHRDAZ-ZUQZANJESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  158
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
  申请人：KIM Norman N.

  公开号：US20110245195A1

  公开（公告）日：2011-10-06

  Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
• US8476247B2
  申请人：——

  公开号：US8476247B2

  公开（公告）日：2013-07-02
• US8895530B2
  申请人：——

  公开号：US8895530B2

  公开（公告）日：2014-11-25
• US9289383B2
  申请人：——

  公开号：US9289383B2

  公开（公告）日：2016-03-22